Wednesday - March 11, 2026

Category Archives: Business

MK Notary Services, LLC – Apostille & Online Notary Expands Global-Ready Document Authentication Services

In today’s global environment, document authentication requires both precision and adaptability,” said Melissa, Founder of MK Notary Services, LLC – Apostille & Online Notary. “Our mission is to guide clients through the notarization and apostille process with clarity and professionalism … Continue reading →

Steven Lovett’s The StrategIQ Mindset™ Becomes an Amazon Bestseller, Challenging Executives to Stop Managing the Present and Start Creating the Future

A strategic leadership playbook for modern executives, Steven Lovett’s bestselling book, The StrategIQ Mindset™ exposes why many leaders optimize their way toward irrelevance and how strategic intelligence creates lasting competitive advantage. The StrategIQ Mindset™, a groundbreaking leadership book by executive … Continue reading →

Johnson & Johnson Secures FDA Approval for TECVAYLI + DARZALEX FASPRO in Relapsed/Refractory Multiple Myeloma: A Potential New Second-Line Standard of Care | Delveinsight

TECVAYLI + DARZALEX FASPRO FDA Approval Johnson & Johnson (NYSE: JNJ)’s Phase 3 MajesTEC-3 data show an 83% reduction in risk of disease progression or death, with 83.3% of patients alive at three years reshaping the multiple myeloma treatment paradigm … Continue reading →

GENFIT’s FDA Orphan Drug Designation for G1090N Opens a New Front in the Race to Treat Acute-on-Chronic Liver Failure | DelveInsight

FDA Orphan Drug Designation for GENFIT’s G1090N With no approved therapy for Acute-on-Chronic Liver Failure (ACLF) and approximately 62K cases recorded across major markets, this FDA designation of GENFIT’s G1090N signals an accelerating race to address one of hepatology’s most … Continue reading →

FDA Grants Priority Review to ENHERTU in Post-Neoadjuvant HER2-Positive Early Breast Cancer: A Market-Shaping Milestone | AstraZeneca and Daiichi Sankyo

FDA Grants Priority Review to ENHERTU in Post-Neoadjuvant HER2-Positive Early Breast Cancer Phase III DESTINY-Breast05 data shows a 53% reduction in invasive disease recurrence or death vs. T-DM1, redefining the standard of care for nearly 16,000 annual post-neoadjuvant patients in … Continue reading →

FDA Accepts NDA for Rusfertide and Grants Priority Review in Polycythemia Vera: A Potential Paradigm Shift in PV Treatment | Takeda, Protagonist Therapeutic

FDA Accepts NDA for Rusfertide and Grants Priority Review in Polycythemia Vera Takeda and Protagonist Therapeutics’ first-in-class hepcidin mimetic moves closer to market as FDA sets Q3 2026 PDUFA date; DelveInsight’s Polycythemia Vera Market Report tracks the full competitive and … Continue reading →